SPRED2 Antibody (6G8): sc-517018

SPRED2 Antibody (6G8) is a mouse monoclonal IgG2a kappa light chain antibody that detects SPRED2 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-SPRED2 antibody (6G8) is available as the non-conjugated form. SPRED2, or Sprouty-related, EVH1 domain-containing protein 2, is a 418 amino acid protein that plays a crucial role in cellular signaling by localizing to the peripheral membrane and containing one WH1 domain, one sprouty domain, and one KBD domain. SPRED2 is expressed in various tissues, including the prostate, skin, liver, salivary gland, and small intestine, and functions primarily as a negative regulator of the MAP kinase (ERK 2) signaling pathway, which is vital for cell growth and differentiation. SPRED2 exists as a homodimer or can form heterodimers with SPRED1, acting as a substrate for tyrosine kinases and thereby inhibiting growth-factor-induced activation of the ERK 2 cascade. Notably, SPRED2 undergoes post-translational modifications, specifically phosphorylation at Tyr 228 or Tyr 231, which triggers ubiquitination and subsequent degradation via the proteasome. This regulation is essential, as abnormal expression of SPRED2 has been linked to various malignant tumors, indicating its potential role in carcinogenesis. Furthermore, mutations or disruptions in the SPRED2 gene that lead to the activation of the ERK 2 pathway can result in dwarfism, highlighting the importance of SPRED2 in developmental processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SPRED2 Antibody (6G8) References:

1. Spred is a Sprouty-related suppressor of Ras signalling.  |  Wakioka, T., et al. 2001. Nature. 412: 647-51. PMID: 11493923
2. Spred-2 suppresses aorta-gonad-mesonephros hematopoiesis by inhibiting MAP kinase activation.  |  Nobuhisa, I., et al. 2004. J Exp Med. 199: 737-42. PMID: 14981116
3. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization.  |  Miyoshi, K., et al. 2004. Oncogene. 23: 5567-76. PMID: 15184877
4. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.  |  Nonami, A., et al. 2004. J Biol Chem. 279: 52543-51. PMID: 15465815
5. Expression and subcellular localization of Spred proteins in mouse and human tissues.  |  Engelhardt, CM., et al. 2004. Histochem Cell Biol. 122: 527-38. PMID: 15580519
6. Distinct requirements for the Sprouty domain for functional activity of Spred proteins.  |  King, JA., et al. 2005. Biochem J. 388: 445-54. PMID: 15683364
7. Gene disruption of Spred-2 causes dwarfism.  |  Bundschu, K., et al. 2005. J Biol Chem. 280: 28572-80. PMID: 15946934
8. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.  |  Yoshida, T., et al. 2006. Oncogene. 25: 6056-66. PMID: 16652141
9. Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination.  |  Lock, P., et al. 2006. Biochem Biophys Res Commun. 351: 1018-23. PMID: 17094949